Sandoz lifts guidance after Humira biosimilar drives another quarter of sales growth

After taking a market share lead in the crowded Humira biosimilar space and with other key launches in the works, Novartis spinout Sandoz is raising its full-year sales guidance.

Sandoz previously communicated that it expects 2024 sales growth to reach mid-single-digit percentages. Now, after reporting second-quarter results, the company said it expects mid- to high-single-digit growth for the year.